Anxiety and Symptom Burden in Hemodialysis Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04143100|
Recruitment Status : Active, not recruiting
First Posted : October 29, 2019
Last Update Posted : September 28, 2021
Anxiety has been identified as a prevalent and significant co-morbid condition in patients with End Stage Renal Disease (ESRD) being treated with hemodialysis. In particular, anxious sensitivity to symptoms commonly experienced by dialysis patients may lead patients to prematurely terminate their dialysis sessions and may have consequences on their dialysis adequacy and overall quality of life.
The proposed study will examine the relationships between anxiety, depression, quality of life, symptom burden and dialysis prescription adherence. The primary regression analyses will be used to predict the influence of anxiety and depression (independently and together) on measures of adherence behaviors.
|Condition or disease||Intervention/treatment|
|Anxiety ESRD||Other: Survey|
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||Anxiety, Symptom Burden, and Dialysis Adherence in In-center Hemodialysis Patients|
|Actual Study Start Date :||August 30, 2019|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2021|
- Other: Survey
For our primary analysis (multiple regression) scores on the GAD-7, BAI and PHQ-9 will be used to predict dialysis adherence, as defined as minutes reduced (total dialysis prescribed -total actual time on machine) while controlling for age and gender.
- Generalized Anxiety Disorder-7 (GAD-7) [ Time Frame: This is a cross-sectional study, with anxiety scores being correlated with previous 6 months of adherence data ]Anxiety measure - higher scores indicate more anxiety
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04143100
|United States, New York|
|The Rogosin Institute|
|New York, New York, United States, 10021|
|Principal Investigator:||Daniel Cukor, PhD||The Rogosin Institute|